Recent news highlights include Fennec's Q4 financial results reporting a loss and missed revenue estimates, as well as the settlement of patent litigation with Cipla delaying generic competition. Coverage initiation by Piper Sandler with an overweight recommendation was also noted.

• Fennec Pharmaceuticals reported a Q4 loss and missed revenue estimates as of March 24, 2026 [N1].
• Pre-market reports on March 23, 2026, included Fennec among companies releasing earnings [N2].
• On March 16, 2026, Fennec announced a settlement agreement with Cipla regarding patent litigation over PEDMARK®, delaying Cipla's generic entry until September 1, 2033 [S1].
• Piper Sandler initiated coverage of Fennec Pharmaceuticals with an overweight recommendation in January 2026 [N2].

Fennec Pharmaceuticals benefits from a protected intellectual property position for PEDMARK® with patents extending to 2039 and regulatory exclusivities that limit generic competition. The recent settlement with Cipla delays generic entry until at least 2033, supporting market exclusivity. The company maintains a strong liquidity position, enabling continued commercialization and potential expansion efforts. Coverage initiation by Piper Sandler with an overweight recommendation indicates some positive market interest. Effective cybersecurity and internal controls support operational stability.

Fennec faces risks from patent challenges and potential invalidation that could erode its intellectual property protection and market exclusivity for PEDMARK®. The company reported a net loss of $9.7 million for the fiscal year ending 2025, indicating ongoing profitability challenges. The pharmaceutical industry’s regulatory and competitive environment may impose additional pressures. Litigation and patent defense efforts can be costly and divert management attention. The company’s limited public disclosure on broader business operations and product pipeline adds uncertainty to its long-term prospects.

Fennec's moat is primarily derived from its intellectual property portfolio protecting PEDMARK®, including patents with expiration dates extending to 2039 and regulatory exclusivities such as Orphan Drug Designation and PUMA. The company actively defends its patents through litigation, as evidenced by the recent settlement with Cipla that delays generic competition. The complexity and cost of pharmaceutical patent litigation, combined with regulatory exclusivities, provide barriers to entry for competitors. However, the company acknowledges risks related to patent challenges, potential invalidation, and the need to maintain trade secrets. The patent protection and regulatory exclusivities form the core of Fennec's competitive advantage in the market for PEDMARK®.

• Intellectual Property Litigation Risks: Fennec is engaged in patent litigation to protect PEDMARK® and faces risks that patents may be invalidated or circumvented, which could materially affect its ability to maintain market exclusivity.
• Patent Expiration and Competition: Patents protecting PEDMARK® expire between 2038 and 2039, and failure to obtain patent term extensions or regulatory exclusivities could lead to increased competition and reduced revenue opportunities.
• Financial Performance and Profitability: The company reported a net loss of $9.7 million for the fiscal year ending 2025, reflecting ongoing challenges in achieving profitability.
• Cybersecurity Risks: Despite having a cybersecurity risk management program, Fennec faces risks from potential cyber-attacks that could disrupt operations or compromise sensitive information.
• Market and Regulatory Risks: Changes in healthcare regulations, reimbursement policies, and market dynamics could adversely impact Fennec's commercialization efforts and financial condition.

• Fennec Pharmaceuticals Inc. is a pharmaceutical company with a product called PEDMARK® (sodium thiosulfate injection).
• The company holds patents related to PEDMARK® with expiration dates ranging from January 2038 to July 2039, including patents licensed from OHSU.
• Fennec has been involved in intellectual property litigation against Cipla Limited and Cipla USA, Inc. regarding Cipla's ANDA application for a generic version of PEDMARK®.
• On March 16, 2026, Fennec settled the litigation with Cipla, agreeing that Cipla will not enter the market with its generic sodium thiosulfate product until September 1, 2033, or earlier under certain circumstances, and the lawsuit will be dismissed with each party bearing their own costs.
• The company plans to vigorously defend its intellectual property rights related to PEDMARK® but acknowledges uncertainty in the outcome of patent challenges.
• Fennec's commercial success depends in part on obtaining and maintaining patent protection and trade secrets, which may be challenged or invalidated.
• The company faces risks from third-party patent infringement claims and the possibility of competitors developing similar or alternative technologies.
• Fennec's financial snapshot as of December 31, 2025, includes cash and equivalents of $36.8 million, current assets of $67.0 million, current liabilities of $10.5 million, resulting in a current ratio of 6.37 and a cash ratio of 3.5.
• For the fiscal year ending December 31, 2025, Fennec reported revenues of $44.6 million and a net loss of $9.7 million, with basic and diluted EPS of -$0.34.
• The company has a lease for office space in Research Triangle Park, North Carolina, and previously had office space in Dublin, Ireland, which terminated in January 2025.
• Fennec's management concluded that internal control over financial reporting was effective as of December 31, 2025.
• The company maintains a cybersecurity risk management program with oversight from its board and management, including a Chief Financial Officer responsible for cybersecurity risk management.
• Fennec's common shares trade on the Nasdaq Capital Market under the ticker 'FENC'.
• Recent news reports indicate Fennec reported a Q4 loss and missed revenue estimates as of March 24, 2026.
• Piper Sandler initiated coverage of Fennec Pharmaceuticals with an overweight recommendation in January 2026.